Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. is positioned favorably due to its promising development pipeline, particularly the differentiated attributes of CRB-701, which is recognized for its superior safety and efficacy metrics in treating cancer. Key opinion leaders (KOLs) suggest that CRB-701's favorable dosing schedule and potential for combination therapies could not only enhance its adoption among physicians but also broaden its addressable market, reinforcing its competitive edge in oncology. Additionally, the trial design's ability to expedite enrollment in high unmet need indications supports a strong likelihood of meeting regulatory timelines, enhancing the potential for CRB-701 to secure accelerated designations that could further de-risk the investment thesis.

Bears say

Corbus Pharmaceuticals Holdings Inc faces significant risks related to the efficacy and approval of its drug candidates CRB-701 and CRB-913, which could hinder their development and negatively affect the company's stock valuation. The potential for failure in clinical trials, along with regulatory delays or rejections, poses a substantial threat to future revenues and overall market perception. Additionally, the competitive landscape, with advanced therapies already available or on the horizon, could create commercial challenges for Corbus, further dimming prospects for its product pipeline.

CRBP has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 5 analysts, CRBP has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.